Mechanism of action and emerging role of immune response modifier therapy in dermatologic conditions.

J Cutan Med Surg

Department of Dermatology, Johns Hopkins University, John Hopkins Outpatient Center, Baltimore, Maryland 21205-0900, USA.

Published: October 2005

Immune response modifiers (IRMs) are agents that target the body's immune system (i.e., cytokines, receptors, and inflammatory cells) to combat disease. Topical IRM therapies, which encompass both proinflammatory and immunosuppressive therapeutics, have been used to successfully treat a number of dermatologic conditions. Proinflammatory treatments include Toll-like receptor agonists (e.g., imiquimod 5% cream) and interferon (e.g., interferon-alpha) therapies, which have been used in the treatment of external genital warts, basal cell carcinoma, and other dermatologic diseases. Immunosuppressive therapies include topical and intralesional corticosteroids, anti-tumor necrosis factor agents (e.g., infliximab and etanercept), and anti-CD4+ T-cell agents, including calcineurin inhibitors and mycophenolate. These agents have been used to treat a number of conditions, including atopic and seborrheic dermatitis and psoriasis. This article reviews the mechanism of action of IRMs and the application of IRMs in several dermatologic diseases.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10227-004-0803-3DOI Listing

Publication Analysis

Top Keywords

mechanism action
8
immune response
8
dermatologic conditions
8
treat number
8
dermatologic diseases
8
action emerging
4
emerging role
4
role immune
4
response modifier
4
modifier therapy
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!